Merck & Co. Inc. closed 41.19% below its 52-week high of $134.63, which the company reached on June 25th.

Given the economic conditions in China, Merck withdrew its previously issued long-term guidance of generating more than $11 billion in sales form Gardasil by 2030. Proquad, M-M-R II and Varivax ...

Merck & Co., Inc. (MRK) said on Tuesday that it hasentered into an exclusive license agreement with China-based Jiangsu Hengrui Pharmaceuticals Co. for an investigational oral drug for heart ...

To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Merck & Co. has entered a competitive race for a new type of heart drug, announcing Tuesday it will pay ...

Merck & Co has made another move towards diversifying its pipeline and reducing its reliance on blockbuster cancer drug Keytruda, pledging $525 million to an alliance with Synthekine initially ...